Table 1 Reimbursement status and recommendations issued for analysed drugs in 2017
Medicine name | Active substance | Approval type | Recommendation/reimbursement In analysed countries | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bulgaria | Croatia | Czechia | Estonia | Hungary | Latvia | Lithuania | Poland | Romania | Slovakia | |||
Adcetris | Brentuximab vedotin | Conditional approval | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ | ✓/✓ | ./✗ | ./✗ | ✓/✓ | ./✗ | ./✗ |
Arzerra | Ofatumumab | Unconditional | ✓/✓ | ✓/✓ | ./✗ | ./✗ | ✗/✗ | ./✗ | ./✗ | ✗/✗ | ✓/✓ | ✓/✓ |
Atriance | Nelarabine | Exceptional circumstances | ✓/✓ | ./✗ | ✓/✗ | ./✗ | ✓/✓ | ✗/✗ | ./✗ | ✓/✓ | ✓/✓ | ./✗ |
Blincyto | Blinatumomab | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ./✗ | ✓/✗ | ./✗ | ./✗ |
Bosulif | Bosutinib | Conditional approval | ✓/✓ | ./✓ | ./✗ | ✓/✓ | ✓/✓ | ✓/✓ | ./✗ | ✗/✓ | ✓/✓ | ./✗ |
Ceplene | Histamine dihydrochloride | Exceptional circumstances | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Cometriq | Cabozantinib | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ./✗ |
Dacogen | Decitabine | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ✓/✓ | ./✗ |
Darzalex | Daratumumab | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ✗/✗ |
Farydak | Panobinostat lactate anhydrous | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ./✗ |
Gazyvaro | Obinutuzumab | Unconditional | ./✗ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ |
Gliolan | 5-aminolevulinic acid hydrochloride | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Iclusig | Ponatinib | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ./✗ | ✓/✗ | ./✗ | ✓/✓ |
Imbruvica | Ibrutinib | Unconditional | ✓/✓ | ./✗ | ./✗ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ | ✗/✓ | ./✗ | ✓/✓ |
Imnovida | Pomalidomide | Unconditional | ./✗ | ./✗ | ✓/✓ | ./✗ | ./✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ✗/✗ |
Kyprolis | Carfilzomib | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Lartruvo | Olaratumab | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Lenvima | Lenvatinib mesylate | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Lynparza | Olaparib | Unconditional | ✓/✓ | ./✓ | ./✗ | ✓/✓ | ./✗ | ./✗ | ✓/✓ | ✗/✓ | ./✗ | ./✗ |
Mepact | Mifamurtide | Unconditional | ./✗ | ./✗ | ✓/✓ | ✓/✓ | ✗/✗ | ./✗ | ./✗ | ✗/✗ | ./✗ | ✗/✗ |
Nexavar | Sorafenib | Unconditional | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ | ✗/✓ | ./✗ | ✓/✓ |
Ninlaro | Ixazomib citrate | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Onivyde | Irinotecan hydrochloride trihydrate | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Revlimid | Lenalidomide | Unconditional | ./✗ | ./✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✗/✗ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ |
Sprycel | Dasatinib | Unconditional | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ |
Tasigna | Nilotinib | Unconditional | ✓/✓ | ✓/✗ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ | ✓/✓ |
Tepadina | Thiotepa | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✓ | ./✗ | ./✗ |
Thalidomide Celgeneb | Thalidomide | Unconditional | ./✗ | ./✗ | ./✗ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ | ✗/✗ | ./✓ | ./✗ |
Torisel | Temsirolimus | Unconditional | ✓/✓ | ✓/✗ | ✓/✓ | ./✗ | ✓/✓ | ✗/✗ | ./✗ | ✗/✓ | ./✗ | ✓/✓ |
Unituxin | Dinutuximab | Unconditional | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Venclyxto | Venetoclax | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Vidaza | Azacitidine | Unconditional | ✓/✓ | ✓/✗ | ✓/✓ | ✓/✓ | ./✗ | ./✗ | ✓/✓ | ✓/✓ | ./✗ | ✓/✓ |
Votubia | Everolimus | Unconditional | ✓/✓ | ✓/✗ | ./✗ | ✓/✓ | ./✗ | ./✗ | ✓/✓ | ✓/✓ | ✓/✓ | ./✗ |
Xaluprinec | 6-mercaptopurine monohydrate | Unconditional | ✓/✓ | ./✗ | ✓/✓ | ✓/✓ | ✓/✓ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |
Yondelis | Trabectedin | Unconditional | ./✗ | ✓/✗ | ./✗ | ./✗ | ✗/✗ | ✗/✗ | ./✗ | ✓/✓ | ✓/✓ | ./✗ |
Zalmoxis | Allogeneic T cells genetically modified | Conditional approval | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ | ./✗ |